Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Net Cash Flow (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Net Cash Flow for 8 consecutive years, with $65.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 612.76% to $65.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, up 449.39% year-over-year, with the annual reading at $28.7 million for FY2025, 449.39% up from the prior year.
  • Net Cash Flow for Q4 2025 was $65.9 million at Precision Biosciences, up from -$13.6 million in the prior quarter.
  • The five-year high for Net Cash Flow was $103.7 million in Q1 2021, with the low at -$31.4 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $2.4 million, with a median of -$13.5 million recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 612.76% in 2025, while the deepest fall reached 506.06% in 2025.
  • Over 5 years, Net Cash Flow stood at -$16.8 million in 2021, then crashed by 33.72% to -$22.5 million in 2022, then soared by 75.29% to -$5.6 million in 2023, then tumbled by 131.59% to -$12.9 million in 2024, then skyrocketed by 612.76% to $65.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $65.9 million, -$13.6 million, and -$15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.